XELJANZ is the first in a class of treatments for moderate to severe RA called Janus kinase (JAK) inhibitors. If methotrexate hasn’t done enough to help relieve your RA symptoms, and before you and your rheumatologist decide on a biologic, ask if XELJANZ is right for you.
XELJANZ has been shown to be effective in reducing the progression of joint damage.
In clinical trials, more than half of XELJANZ patients felt an improvement in RA symptoms at 3 months. In some patients, XELJANZ began to work in as early as 2 weeks to reduce RA joint pain and swelling.
Everyone is different. Your results may vary.
XELJANZ can be taken without methotrexate, and has been shown to help people manage their RA symptoms whether taken with or without it.
†The Arthritis Foundation’s Ease-of-Use Commendation recognizes products, such as the XELJANZ bottle cap, proven to make life easier for people who have arthritis and other physical limitations.
How XELJANZ Works
XELJANZ is a Janus kinase (JAK) inhibitor that works deep inside the cell to disrupt activities occurring in signaling pathways. These JAK pathways are believed to play a role in the inflammation associated with RA. Watch to learn more about the science of XELJANZ and how it works to help disrupt the processes that can lead to inflammation.
Take a closer look at how XELJANZ works.